Industry News

MPI Research opened the 10,000-sf Translational Imaging Center in May of 2014 in Mattawan, Mich. Created in partnership with 3D Imaging and inviCRO, the two-story facility will support advanced drug discovery research by providing molecular imaging, autoradiography, and animal modeling in a single location. The project is designed to expedite the translation of preclinical data into clinical data to mitigate risk in the pharmaceutical development process and includes a cyclotron and a vivarium.

Cubresa introduced a compact, affordable SPECT scanner for preclinical research in early 2014. The scanner attaches to existing small animal CT systems, transforming them into multi-modality molecular imaging systems for disease study, translational research, and drug discovery applications. The product features a slim bore which positions the imaging detectors close to the animal subject, optimizing spatial resolution. Advanced detector technology improves sensitivity to balance radiation dose with accelerated study throughput.

Charles River Laboratories opened a 58,000-sf animal research facility in April of 2014 in Spencerville, Ohio. The building provides vivarium space and labs for preclinical research on pharmaceutical compounds, medical devices, and chemicals. Construction on the facility began in 2007 and was halted in 2009, with recommencement of building work in October of 2013.

The Jackson Laboratory (JAX) and the University of California, Davis have initiated a new phase in their ongoing research collaboration by sharing resources and core services. UC Davis will benefit from on-site educational programs at the JAX mouse facility in Sacramento, Calif. JAX will provide mouse colony management services for UC Davis investigators, expediting research discoveries by preventing transportation delays.

TNO Triskelion opened a BSL-3 vaccine testing laboratory in March of 2014 in Zeist. The facility will enable the contract research organization to develop drugs to combat viruses including avian influenza, SARS, and tuberculosis. The biocontainment lab conforms to GLP (Good Laboratory Practice) standards and is able to test treatments against all subtypes of influenza, whether avian or human.